U.S. markets open in 2 hours 51 minutes
  • S&P Futures

    4,074.25
    +69.50 (+1.74%)
     
  • Dow Futures

    32,643.00
    +484.00 (+1.51%)
     
  • Nasdaq Futures

    12,502.00
    +257.25 (+2.10%)
     
  • Russell 2000 Futures

    1,816.20
    +33.80 (+1.90%)
     
  • Crude Oil

    115.15
    +0.95 (+0.83%)
     
  • Gold

    1,827.70
    +13.70 (+0.76%)
     
  • Silver

    21.83
    +0.27 (+1.27%)
     
  • EUR/USD

    1.0527
    +0.0089 (+0.85%)
     
  • 10-Yr Bond

    2.8770
    0.0000 (0.00%)
     
  • Vix

    26.69
    -2.18 (-7.55%)
     
  • GBP/USD

    1.2473
    +0.0150 (+1.21%)
     
  • USD/JPY

    129.2720
    +0.2190 (+0.17%)
     
  • BTC-USD

    30,538.00
    +668.13 (+2.24%)
     
  • CMC Crypto 200

    685.64
    +442.96 (+182.53%)
     
  • FTSE 100

    7,530.35
    +65.55 (+0.88%)
     
  • Nikkei 225

    26,659.75
    +112.70 (+0.42%)
     

Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?

Given this risk, we thought we'd take a look at whether Checkpoint Therapeutics (NASDAQ:CKPT) shareholders should be worried about its cash burn. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.

View our latest analysis for Checkpoint Therapeutics

Does Checkpoint Therapeutics Have A Long Cash Runway?

A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. In March 2021, Checkpoint Therapeutics had US$60m in cash, and was debt-free. Looking at the last year, the company burnt through US$17m. That means it had a cash runway of about 3.6 years as of March 2021. Importantly, analysts think that Checkpoint Therapeutics will reach cashflow breakeven in 4 years. Essentially, that means the company will either reduce its cash burn, or else require more cash. The image below shows how its cash balance has been changing over the last few years.

debt-equity-history-analysis
debt-equity-history-analysis

How Is Checkpoint Therapeutics' Cash Burn Changing Over Time?

In our view, Checkpoint Therapeutics doesn't yet produce significant amounts of operating revenue, since it reported just US$165k in the last twelve months. Therefore, for the purposes of this analysis we'll focus on how the cash burn is tracking. As it happens, the company's cash burn reduced by 5.9% over the last year, which suggests that management are maintaining a fairly steady rate of business development, albeit with a slight decrease in spending. Clearly, however, the crucial factor is whether the company will grow its business going forward. So you might want to take a peek at how much the company is expected to grow in the next few years.

How Hard Would It Be For Checkpoint Therapeutics To Raise More Cash For Growth?

Even though it has reduced its cash burn recently, shareholders should still consider how easy it would be for Checkpoint Therapeutics to raise more cash in the future. Companies can raise capital through either debt or equity. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).

Since it has a market capitalisation of US$202m, Checkpoint Therapeutics' US$17m in cash burn equates to about 8.3% of its market value. Given that is a rather small percentage, it would probably be really easy for the company to fund another year's growth by issuing some new shares to investors, or even by taking out a loan.

Is Checkpoint Therapeutics' Cash Burn A Worry?

As you can probably tell by now, we're not too worried about Checkpoint Therapeutics' cash burn. In particular, we think its cash runway stands out as evidence that the company is well on top of its spending. On this analysis its cash burn reduction was its weakest feature, but we are not concerned about it. Shareholders can take heart from the fact that analysts are forecasting it will reach breakeven. Looking at all the measures in this article, together, we're not worried about its rate of cash burn; the company seems well on top of its medium-term spending needs. On another note, we conducted an in-depth investigation of the company, and identified 3 warning signs for Checkpoint Therapeutics (1 is concerning!) that you should be aware of before investing here.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies, and this list of stocks growth stocks (according to analyst forecasts)

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.